Home > Journals > Panminerva Medica > Past Issues > Panminerva Medica 2017 March;59(1) > Panminerva Medica 2017 March;59(1):107-13

CURRENT ISSUE
 

ARTICLE TOOLS

Publication history
Reprints
Cite this article as

PANMINERVA MEDICA

A Journal on Internal Medicine


Indexed/Abstracted in: BIOSIS Previews, Current Contents/Clinical Medicine, EMBASE, PubMed/MEDLINE, Science Citation Index Expanded (SciSearch), Scopus
Impact Factor 1,698


eTOC

 

REVIEW  


Panminerva Medica 2017 March;59(1):107-13

DOI: 10.23736/S0031-0808.16.03212-2

Copyright © 2016 EDIZIONI MINERVA MEDICA

language: English

PON1 L55M polymorphism might contribute to the risk of cancer

Peizeng HU 1, 2, Yongchen MA 1, 2, Lingling ZHANG 3, Sheng MA 1

1 Yidu Central Hospital, Weifang, China; 2 School of Medicine, Shandong University, Jinan, China; 3 Shandong Province Rongjun Hospital, Weifang, China


PDF  


INTRODUCTION: The results involved in correlation of PON1 L55M polymorphism and cancer risk are still inconsistent and controversial. Therefore, we performed this comprehensive meta-analysis for the effects of PON1 L55M polymorphism and cancer risk.
EVIDENCE ACQUISITION: We carried out a database search in PubMed (Medline) and EMBASE covering all published articles. The strength of association between PON1 L55M polymorphism and cancer risk was estimated by pooled ORs with corresponding 95% confidence intervals (CI).
EVIDENCE SYNTHESIS: Twenty-one independent case-control studies concerned with association between PON1 L55M polymorphism and cancer risk were finally included in this meta-analysis. We found that there was a statistical significance between PON1 L55M polymorphism and cancer risk (OR=1.21, 95% CI: 1.04-1.40). In stratified analyses by site of cancer, statistically significant increased breast cancer risk was found (OR=2.04, 95% CI: 1.29-3.21). In stratified analyses by ethnicity, statistically significant increased cancer risk was found in Caucasian populations (OR=1.25, 95% CI: 1.03-1.51). In stratified analyses by source of control, significant increased cancer risk was found in hospital-based studies (OR=1.26, 95% CI: 1.10-1.44).
CONCLUSIONS: This meta-analysis suggested that PON1 L55M polymorphism might increase the risk of cancer.


KEY WORDS: Human PON1 protein - Neoplasms - Biomarkers - Meta-analysis

top of page

Publication History

Issue published online: January 16, 2017
Article first published online: June 16, 2016

Cite this article as

Hu P, Ma Y, Zhang L, Ma S. PON1 L55M polymorphism might contribute to the risk of cancer. Panminerva Med 2017;59:107-13. DOI: 10.23736/S0031-0808.16.03212-2

Corresponding author e-mail

peizengsd@163.com